Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

BACKGROUND: Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xu, Briaux, Adrien, Becette, Véronique, Benoist, Camille, Boulai, Anais, Chemlali, Walid, Schnitzler, Anne, Baulande, Sylvain, Rivera, Sofia, Mouret-Reynier, Marie-Ange, Bouvet, Laurence Venat, De La Motte Rouge, Thibaut, Lemonnier, Jérôme, Lerebours, Florence, Callens, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180434/
https://www.ncbi.nlm.nih.gov/pubmed/30305115
http://dx.doi.org/10.1186/s13045-018-0670-9

Ejemplares similares

Ejemplares similares